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A PHARMACOLOGICAL STRATEGY AGAINAST AFRICAN SLEEPING SICKNESS 
 Wahaj Zuberi, B.S. 
Advisory Professor: Nayun Kim, Ph.D. 
 
 Trypanosoma brucei is a parasitic eukaryote and is the causal agent of the 
disease known as African sleeping sickness, transmitted via the bite of a tsetse fly. If 
left untreated, the parasite ultimately crosses the blood-brain barrier eventually 
leading to death. Currently there are five approved drugs used to treat it, each with 
toxic side effects and effective at specific disease stages. A more effective and less 
toxic drug candidate is highly sought after. The essential enzyme, dUTPase, may be 
an excellent drug target in the parasite and can be tested utilizing S. cerevisiae as a 
model system. 
dUTPase is essential in T. brucei (tbdUTPase), yeast (yDut1), and humans 
(hDUT). dUTPase being a dimer in T. brucei, but a trimer in yeast and humans, we 
hypothesize there may be a molecule that inhibits the function of tbdUTPase, but not 
of yDut1 and hDUT. The endogenous yDut1 was knocked down via auxin inducible 
degron system in order to complement its loss by transforming plasmids containing 
human and T. brucei dUTPase genes. Induced expression of hDUT and tbdUTPase 
did not seem to complement the loss of yDut1. As an alternative strategy, the 
dUTPase genes from human and T. brucei were next integrated into the yeast 
genome at the inactive HO locus. The results of this experiment were inconclusive 
and remain to be further explored.  
In order to identify a small molecule ligand of tbdUTPase, a high throughput 
virtual drug screen was performed through Schrödinger’s Suite. This led to the 
discovery of 13 molecules that bind to tbdUTPase but not to hDUT. Out of the 13, 
one molecule showed cytotoxic effects against the parasite but not against yeast.  
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 To determine if the single molecule found was dUTPase specific, yDut1, 
hDUT, and tbdUTPase proteins were purified and their enzymatic activity was 
measured in the presence of the single molecule. The results indicated that the 
molecule found to have cytotoxic effect against T. brucei cells was not dUTPase 
specific. Although the results do not support the initial hypothesis, the dUTPase 
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Chapter 1: Introduction 
 2 
1.1 African Sleeping Sickness 
Human African trypanosomiasis, or African sleeping sickness, is an infectious 
disease caused by the parasitic eukaryote Trypanosoma brucei. Transmitted by the 
bite of a tsetse fly, this disease is a significant problem and restricted to the sub-
Saharan region of Africa [1]. There are two pathogenic subspecies of T. brucei: 1) T. 
b. gambiense is the causal agent of Western African sleeping sickness, responsible 
for over 90% of sleeping sickness cases, and causes chronic sleeping sickness; 2) 
T. b. rhodesiense is the causal agent of Eastern African sleeping sickness and 
causes more acute sleeping sickness [2].    
There are two stages to the disease, the first is called the hemo-lymphatic 
stage, in which the parasite is present in the bloodstream and lymphatic system, and 
the second is called the meningo-encephalitic stage where the parasite has crossed 
the blood-brain barrier resulting in neurological damage [1]. Ultimately if left 
untreated, patients gradually progress into a coma followed by possible organ failure 
and finally death. Rhodesiense sleeping sickness progresses faster with death 
resulting within months, whereas death with Gambiense sleeping sickness can take 
years [3]. The signs and symptoms of the disease caused by the two subspecies are 
overall the same In the first stage of the disease, the leading and most common 
symptoms include fever, headaches, weakness, pruritus, lymphadenopathy, and in 
some cases hepatosplenomegaly. In the second stage of the disease, sleeping 
disorder is the primary symptom followed by neurological symptoms, such as various 
movement and speech disorders [1]. This disease often also has the risk of being 
misdiagnosed due to similarities with other fever-causing and neuropsychiatric 
diseases/problems.  
Diagnosing African sleeping sickness is a two-stage process: screening 
followed by diagnostic confirmation [2]. The best test in terms of practicality and 
speed to diagnose African sleeping sickness is by the card agglutination test for 
 3 
trypanosomiasis (CATT). This is a serological test that detects trypanosome-specific 
antibody in blood, plasma, or serum and the agglutination reaction is then analyzed 
visually [1, 4]. Other serological and molecular assays are available; however, they 
are to be analyzed with caution due to lack of personnel training, laboratory testing 
facilities, and poor accuracy and reproducibility [5]. Positive results from these 
methods require further validation. The best method for confirmation is microscopic 
examination of the lymph node aspirate, blood, or cerebral spinal fluid for the 
presence of the parasite [1]. 
Development of a proper and viable treatment against the parasite has been 
difficult and unfeasible due to the presence of approximately 2000 variant surface 
glycoproteins (VSG) [1]. When infection initially occurs, the initial surface 
glycoproteins are recognized by the host immune system, leading to the production 
of appropriate antibodies. These antibodies are able to combat the presence of the 
parasite; however, the parasite is simultaneously changing its surface glycoprotein, 
so that it is no longer affected by the initial antibodies [6]. This cycle repeats itself 
ultimately leading to the host’s immune system being unable to eliminate 
trypanosome [7]. Currently there are five drugs that are routinely used against 
African sleeping sickness: pentamidine and suramin are used to treat first-stage 
disease, and melarsoprol, eflornithine, and nifurtimox are used to treat the second-
stage disease [5]. Diagnosis and treatment using first-stage drugs as early as 
possible are vital to increase the chance of a patient being cured. The drugs 
effective against the second stage of the disease run a significantly higher risk of 
toxic side effects, due to a greater level of complexity in administration, since it is 
necessary for them to cross the blood-brain barrier [5].  
Treatment for African sleeping sickness is variable based on the stage of the 
disease and the subspecies that has infected the patient [8]. For T. b. gambiense, 
pentamidine is effective in the first stage of disease and eflornithine in combination 
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with nifurtimox is effective in the second stage of disease. For T. b. rhodesiense, 
suramin is effective in the first stage of disease and melarsoprol is effective in the 
second stage of disease.  
For T. b. gambiense, the first choice of treatment is pentamidine [1, 5, 9]. 
Pentamidine is administered intramuscularly once daily over a span of 7 days, but 
can also be given intravenously. if diluted in saline beforehand. When administered, 
it is also followed by the administration of sugar, as hypoglycemia is one of the 
adverse side effects of the drug. In addition, other effects include pain and swelling 
at the injection site, hypotension, and gastrointestinal problems. Eflornithine is the 
first choice of treatment for patients for whom the disease has progressed to the 
second stage. More recently, eflornithine has been administered in combination with 
a second drug called nifurtimox. This nifurtimox-eflornithine combination therapy 
(NECT) has been shown to have higher cure rates along with lower fatality rates and 
less severe adverse effects [5]. Eflornithine is given as a monotherapy if nifurtimox 
is unavailable. With a complete NECT kit, nifurtimox is administered orally and 
eflornithine is administered intravenously. In combination, nifurtimox is given to the 
patient for ten days with three doses each day and eflornithine is given every twelve 
hours. If only eflornithine is administered, four infusions are given daily for fourteen 
days. For the NECT treatment, common side effects are abdominal pain, nausea, 
and headaches, whereas when eflornithine is given as a monotherapy side effects 
are more severe, leading to pruritus, diarrhea, myelosuppression, and even seizures 
[1, 5, 9]. 
For T. b. rhodesiense, the first choice of treatment is the drug suramin [10]. 
Suramin rapidly deteriorates once it is diluted and needs to be administered to the 
patient immediately intravenously. This drug is more complex to administer, since it 
requires a schedule, that varies with each patient and can require treatments for up 
to one month. In addition, it requires a test dose to avoid the risk of hypersensitivity 
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reactions [5]. Adverse side for suramin effects are typically mild and reversible 
including nephrotoxicity, neuropathy, agranulocytosis, and thrombocytopenia [1]. 
Melarsoprol is the final choice of treatment for patients who have progressed to the 
second stage of the disease. Melarsoprol is the most toxic drug out of the five that 
have been mentioned and is restricted to only be used for treating second stage T. b. 
rhodesiense disease [11]. The most important severe side effect as a result of 
melarsoprol treatment, administered intravenously every day for ten days, is an 
encephalopathic syndrome that leads to the death in majority of patients who are 
diagnosed with it. Patients are closely monitored to avoid progression of the 
encephalopathic syndrome [1, 5]. 
 
1.2 dUTPase/Uracil in DNA 
There are many different mechanisms by which DNA modifications can occur through 
exogenous and endogenous damaging factors. One form of endogenous DNA modification is 
the incorporation of uracil into DNA [12]. Uracil can appear in DNA through two different 
methods, 1) cytosine deamination and 2) uracil incorporation into DNA instead of thymine 
during DNA replication/repair [13].  
The rate of cytosine deamination is greatly increased when DNA is single-stranded, 
such as during DNA replication [14]. The newly incorporated uracil create premutagenic U:G 
mispairs. This can result in a transition from C:G to T:A since DNA polymerase effectively and 
efficiently incorporates adenine that pairs with the  uracil and this is followed by the removal of 
uracil and incorporation of thymine in its place [15-17]. It has been calculated that cytosine 
deamination occurs in approximately 70 to 200 cytosine base pairs per day in every human cell 
[17]. Cytosines in different forms, such as in cyclobutene dimers are deaminated faster than 
other cytosines. Cytosine can also be deaminated enzymatically by enzymes, such as 
activation-induced deaminase, which has been suggested to target C:G base pairs directly 
[16].  
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The other source of uracil incorporation into DNA is through the normal function of 
eukaryotic DNA polymerase [7]. Deoxyuridine triphosphate (dUTP) is incorporated into DNA 
rather than deoxythymidine triphosphate (dTTP). DNA polymerases cannot distinguish between 
uracil and thymine base pairs, therefore uracil is freely incorporated into DNA rather than the 
appropriate thymine base pairs, depending on the available ratio of [dUTP/dTTP] (Figure 1) 
[7]. This however, results in stable U:A base pairing, which are not mutagenic,  in contrast to 




Figure 1: Uracil (dUTP) can be incorporated into DNA. 
Both dUTP and dTTP can be incorporated into DNA via DNA Polymerase. The presence of 



















The thymidine synthesis pathway is the only pathway for the synthesis of thymine to be 
used during DNA replication via DNA polymerase [19]. Deoxyuridine triphosphate 
diphosphatase (dUTPase), Dut1 in S. cerevisiae, is an essential enzyme that hydrolyzes dUTP 
to deoxyuridine monophosphate (dUMP), a substrate for dTTP synthesis via other downstream 
enzymes to be used for appropriate DNA replication. This regulates the extent of uracil being 
incorporated into the DNA. Uracil in DNA is the cause of major mutations, in yeast, which 
ultimately lead to thymine-less cell death (Figure 2) [20, 21]. This occurs due to the increased 
































Figure 2: Uracil-mediated DNA damage. 
When uracil is incorporated into DNA, this activates the enzyme uracil DNA-glycosylase, which 
removes uracil from DNA. This removal of uracil forms an AP site within in DNA and an 
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The mechanism to remove uracil from DNA utilizes the enzyme uracil DNA glycosylase, 
Ung1 in S. cerevisiae [22]. When uracil is incorporated, Ung1 activates and removes uracil 
from DNA resulting in the formation of a lesion called apurinic/apyrimidinic (AP) sites or abasic 
sites. AP sites act to block DNA replication/repair machinery, leading to destructive outcomes, 
such as single-strand and double-strand breaks, resulting in fragmentation and ultimately cell 
death [13]. To prevent cell death, the base excision response (BER) pathway is initiated in 
response to specific proteins, in this case uracil DNA glycosylase. Following the removal of 
uracil and creation of AP sites, AP endonuclease proteins, such as APN1, incise the remaining 
phosphodiester bonds generating 3’-hydroxyl and 5’-deoxyribose phosphate sections. The 
5’deoxyribose phosphate end is removed by DNA deoxyribophosphodiesterase leading to the 
single gaps being correctly filled in by DNA polymerase activity and further followed by DNA 
ligase activity to restore DNA integrity [23]. Furthermore, the mechanism as to which uracil 
DNA glycosylase-mediated repair is conducted varies with the initial position of uracil in the 
DNA relative to the replication fork [16].  
In the absence of Dut1, the frequency of uracil incorporation into DNA increases due to 
the increase in [dUTP/dTTP] ratio, further increasing the activity of UNG1 leading to more AP 
sites and eventually cell death, making Dut1 an essential enzyme [24].  All dUTPase enzymes 
are essential enzymes in both eukaryotic and prokaryotic organisms, making this an excellent 
protein/pathway to target with various dUTPase inhibiting small compounds, such as in T. 
brucei [21]. In addition, sequence differences and structural differences in the dUTPase 
enzyme also make it a desirable protein/pathway to target. The S. cerevisiae and human 
dUTPase enzymes are both homo-trimers formed by beta-sheets and the T. brucei dUTPase 
enzyme is a homo-dimer formed by alpha helices [24, 25].  
The thymidine synthesis pathway is one of the most commonly targeted pathways used 
to treat various types of cancer [11]. Downstream of dUTPase is the enzyme thymidylate 
synthase (TS), which converts dUMP to dTMP using the methyl donor 5,10-
methyltetrahydrofolate (5,10-CH2 THF). This step is essential since dTMP is required for dTTP 
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production, an essential precursor for DNA replication and repair. TS functions as a 
homodimer, containing a substrate binding site for the nucleotide dUMP and a cofactor binding 
pocket for 5,10-CH2 THF. The inhibition of TS can be achieved by blocking either of the two 
sites. The substrate binding site can be blocked by nucleotide analogs and antifolates such as 
5-fluorouracil (5-FU) and methotrexate (MTX), respectively [19, 26]. Any inhibition of TS leads 
to the increase in uracil level ultimately leading to thymine-less death via the UNG1 mediated 
repair pathway. dUTPase counteracts high levels of uracil, supplying additional pools of dUMP 
for TS activity to generate dTMP. dUTPase levels and activity can directly influence the very 
common TS-based treatment in many patients [19]. Further lowering the activity of dUTPase 
along with a TS-based treatment can help treat cancer patients, increasing the chances of 
success.  
 
1.3 Auxin Inducible Degron System  
Studying the consequences of null mutations is a very common and practical approach 
to study the function of a gene product in vivo. However, in the case of essential genes 
required for growth, these mutations must be conditional. Effective methods for studying 
essential genes utilize constructing temperature-sensitive mutants or constructing mutants with 
a regulatable promoter [27]. However, these two methods are problematic because 
temperature sensitive mutants can laborious to generate and regulatable promoters can be 
leaky. A relatively new method, the auxin-inducible degron (AID), is a technique that is able to 
conditionally mutate a gene by degrading the target protein with no side effect in non-plant 
eukaryotes. Indole-3-acetic acid (IAA), or auxin, is a plant hormone responsible for regulating 
plant growth [28]. This compound is only found in plants, therefore when it is used in other 
organisms such as S. cerevisiae, it can be concluded that any change resulting from addition of 
AID is due to the presence of auxin. In budding yeast, the AID system has been successfully 
applied to several proteins including Dut1. The AID system utilizes the SCF E3 ubiquitin ligase 
complex in which auxin acts as the initiator to proteasome-mediated degradation [27, 29]. 
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Initially, the target gene is fused with an IAA transcriptional regulator, which acts as the degron 
tag to induce degradation when auxin binds to it. This is followed by interaction with the F-box 
protein, TIR1, part of the SCF complex, which contains the recognition domain. Once properly 
recognized, the target protein is ubiquitylated via the E3 ubiquitin ligase, ultimately leading to its 
degradation by the proteasome (Figure 3).  
 
  
Figure 3: Auxin inducible degron system. 
The addition of auxin to the culture medium among non-plant organisms, modified with degron 
tag and TIR1 F-box protein, allows for the rapid degradation of a protein of interest. Firstly, 
auxin binds to the degron tag, which then allows for the interaction with the TIR1, part of the 
whole SCF complex. The target protein is then ubiquitylated by  E3 ubiquitin ligase, ultimately 












Papagiannakis et al., (2017) have more recently demonstrated the effectiveness of the 
AID system, easily applying it to S. cerevisiae [29]. Utilizing the ubiquitin-mediated protein 
degradation system along with AID system, they were able to eliminate essential proteins of 
interest and create conditional mutants. The two genes they targeted were Cdc28 and Cdc14, 
both essential cell cycle proteins. Upon the addition of 0.1 mM auxin, they were able to show 
the AID system efficiently depleted the two cell-cycle proteins. 
 
1.4 Schrödinger’s Virtual Drug Screen 
The conventional method for drug screening is known as high-throughput screening 
(HTS) [30, 31]. Specifically, for structure-based drug design, a vast number of molecules are 
each subjected to a reaction in the presence of a target protein, cell, etc. Depending on the 
assay, observational changes are then measured either by machine or manually to determine 
the effectiveness of the molecules being tested. This process, however, is very tedious, time 
consuming, and not cost effective considering that simply finding a potential candidate in a drug 
screen is only a starting point [32]. The advancements in technology has opened new 
possibilities for computer-aided drug discovery tools for a faster and more cost-efficient 
method, otherwise known as virtual screening [33]. 
Schrödinger is an emerging company in the field of biotechnology. Schrödinger offers a 
suite of programs that allow in silico simulation of molecular docking. This is achieved by using 
their physics-based computational platform, which allows users to evaluate a large selection of 
online available molecules to search for solutions through interactive and predictive modeling, 
molecule design, and molecular simulations. Glide is one of the programs in the Schrödinger 
suite, which allows for studying ligand-receptor docking [34]. For structure-based drug design, 
any protein structure can be uploaded to the software, if crystal structures are available. These 
structures can then be further prepared to simulate an active enzyme, for example adding a 
magnesium cofactor to a human dUTPase protein. A large database of ligands can then be run 
against the protein structure’s active site with the software calculating multiple thermodynamic 
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variables. Two of these variables, docking score and binding energy, indicate how well the 
ligand fits into the protein’s active site and how strongly the ligand binds, respectively. 
Computational docking is becoming a widespread norm in the field of pharmaceuticals 
and biotechnology due to the programs high-throughput screening capability. This allows for a 
plethora of compounds to be screened for biological activity. With crystal structures available 
for all varieties of proteins, Schrödinger’s virtual drug screening program allows the user to 
upload the structure to be studied, allowing for discovery at a much-accelerated rate. The 
uploaded protein structure can be modified to allow for a better suited structure-based drug 
design. Glide offers a range of screening modes, each with a varying screening speed and 
accuracy hits: high-throughput virtual screening (HTVS) is the fastest screening method to 
easily screen through millions of ligands, standard precision (SP) screens through thousands of 
ligands, and lastly extra precision (XP) screens through dozens to hundreds of ligands with the 
best accuracy scoring. Overall, Schrödinger’s Glide allows for the user to achieve faster and 
more accurate drug design, dramatically reducing research and development costs and 
increasing productivity.  
The combination of model organism-based genetic approach and virtual drug 
screening allows for a comprehensive inquiry of potential drugs and small molecules 
for a specific target. Structural differences in essential enzymes, such as dUTPase, 
in various organisms ranging from humans to trypanosomes brings forth the 
question: can a molecule be found that is toxic to one but not to the other? This 
study explores both an organism model and virtual drug screening in order to 
address this question. Specifically, such combinatorial approaches will be used to 
search for a molecule toxic to the pathogenic parasite T. brucei and not to the human 
host. Furthermore, this opens a pathway to a more cost-and time-efficient 
pharmacological strategy to be able to combat against various infectious diseases 
such as African sleeping sickness. 
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Chapter 2: Materials and Methods
 15 
2.1 Plasmids and Yeast Strains 
 The plasmids and yeast strains used for this project are listed in Table 1. 
Table 1: Plasmids and Yeast Strains 
Plasmids Description Origin 
pNK14 vector pRS426 Previous study 
pNK57 vector p426GAL1 Previous study 
pNK258 yDUT1-3xHA; BamHI (5') and EcoRI (3') This study 
pNK259 hDUT-3xHA; BamHI (5') and EcoRI (3') This study 
pNK260 tbdUTPase-3xHA; BamHI (5') and EcoRI (3') This study 
pNK264 pGal-yDUT1-3xHA; BamHI-EcoRI fragment from PNK258 cloned into PNK57 This study 
pNK265 pGal-hDUT-3xHA; BamHI-EcoRI fragment from PNK259 cloned into PNK57 This study 
pNK266 pGal-tbdUTPase-3xHA; BamHI-EcoRI fragment from PNK260 cloned into PNK57 This study 
pNK285 
HO(SacI)-pGal-hDUT-URA3-HO(MfeI); flanked 
hDUT expression cassette with restriction sites SacI 




tbdUTPase expression cassette with restriction sites 
SacI and MfeI along with HO locus sequence 
This study 
pNK290 removed portion of tbdUTPase gene in PNK286 with restriction enzyme SpeI This study 




pNK297 PNK296 transformed into BL21(DE3) competent cells This study 
pNK301 yDUT1 removed via restriction enzymes NdeI and 
XhoI; ligated hDUT gene via PCR This study 
pNK303 PNK301 transformed into BL21(DE3) competent cells This study 
 
 16 
Table 1. Cont.  
Plasmids Description Origin 
pNK304 yDUT1 removed via restriction enzymes NdeI and 
XhoI; ligated tbdUTPase gene via PCR This study 
pNK305 PNK304 transformed into BL21(DE3) competent cells This study 





Yeast Strains Description Origin 
YNK355 -LEU strain Previous study 
YNK421 WT yDUT1; AFB2 gene integrated into ADE2 locus This study 
YNK425 auxin inducible degron (AID) 6xFLAG tag added to 3' end of yDUT1 in YNK421 This study 
YNK679 ung1Δ in YNK425 This study 
YNK684 URA3 marker; ung1Δ loxed-out  This study 
YNK756 
hDUT expression cassette integrated into HO locus 




tbdUTPase expression cassette integrated into HO 
locus of YNK425 under the control of pGal promoter 
with URA3 marker 
This study 
YNK760 
inactive tbdUTPase expression cassette integrated 
into HO locus of YNK425 under the control of pGal 
promoter with URA3 marker 
This study 
YNK766 URA3 marker removed from YNK756 This study 
YNK767 URA3 marker removed from YNK757 This study 
YNK769 URA3 marker removed from YNK760 This study 
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2.2 Auxin Growth Assays  
All yeast growth was performed at 30°C. To determine viable cells by the CFU 
assay, strains YNK421, YNK425, and YNK355 were streaked out on to agar plates 
containing yeast extract, peptone, and 2% dextrose (YEPD) and overnight 1mL 
overnight cultures were grown in liquid YEPD as well. For YNK355, 5 mL cultures in 
YEPD were grown. From the overnight cultures for YNK421 and YNK425, sub-
cultures were made by adding 20 µL to 1 mL YEPD containing auxin (EtOH soluble 
auxin: Spectrum Chemicals; IN125 and H2O soluble auxin: Sigma-Aldrich, I5148) at 
concentrations of 0, 5, 50, and 100 µM. YNK355 cells were left growing in 30°C. 
After 24 hours, YNK421 and YNK425 cells were centrifuged and collected in 1.5 mL 
micro-centrifuge tubes, washed with 1 mL H2O, centrifuged again and resuspended 
in 200 µL of H2O. For YNK355, 5 mL cultures were collected in 50 mL tubes and 
centrifuged at 3000 x g for 5 minutes and washed and resuspended in 50 mL of H2O. 
YNK421 and YNK425 cells were diluted by a factor of 1x106 in YNK355 cell solution 
and plated on agar plates containing synthetic dextrose LEU dropped out (SD-LEU). 
THE CFU were counted after 4 days of growth and survival percentages were 
calculated.  
For the spot growth assay, strains YNK421 and YNK425 were streaked out on 
YEPD and colonies on YEPD plates were used to inoculate overnight cultures in 
YEPD. Overnight cultures were diluted to an OD600nm of 1 (approximately 5x107 
cells/mL) and serial dilutions were made ranging from 1x106 to 1x103 cells/mL. The 
dilutions (5 µL) were spotted on YEPD plates containing auxin (0, 50, 100, 500 uM) 
and incubated at 30°C for 24 hrs. 
 
2.3 Auxin Growth Curves 
Growth curves were created by measuring absorbance on the BioTek Synergy 
plate reader at a wavelength of 600 nm. All readings were performed for 18 to 24 
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hours. From overnight cultures, 100 µL was added to 5mL of media and incubated 
again until OD600nm reached 0.6 to 0.8 and then diluted 0.1 at a final volume of 200 
µL within the 96-well plate. The following auxin [ethanol/water soluble] 
concentrations were used, diluted using either YEPD media or YEP-GE [YEP-GE 
composition with and without galactose]: 0, 5, 50, and 500 µM. 5-fluorouracil (5-FU) 
was also used with auxin at the concentration of 25 µM for specific treatment 
targeting the thymidine synthesis pathway. 
 
2.4 High Throughput Virtual Screen using Schrödinger’s suite.  
High throughput virtual screening (HTVS) was performed using Schrödinger’s 
Glide software. For the three-dimensional (3D) crystal structure of T. brucei dUTPase, 
the 1.47 Å resolution T. brucei dUTPase structure (PDB ID: 4DK2) and (PDB ID:4DL8) [25] 
with the “Search Space” defined as the annotated catalytic center where dUTP/dUMP binds 
were used. For the docking simulation of the human DUT enzyme, the annotated 
structures from the PDB database were used (PDB ID: IQ5U and 3ARA) [35, 36]. A custom 
library of 5000 compounds (“Tainer 5000”) selected from the Life Chemical library for their 
variety, low toxicity, and drug-like properties according to the Lipinski’s rules was used as the 
ligand library [37].   Compounds were first screened for docking into the tbdUTPase 
and hDUT structures’ active site.  
 
2.5 T. brucei/Yeast Growth Curves 
The 13 molecules identified through HTVS were provided by Dr. John Tainer 
from MD Anderson Cancer Center. The strain YNK421 was cultured in YEPD media 
in a 96-well plate at a volume of 200 µL with the starting OD600nm of 0.1 with 
absorbance readings recorded at a wavelength of 600nm on the BioTek Synergy 
Plate Reader. OD600nm readings were taken every 15 minutes for 20 hours. The final 
concentration for each of the 13 molecules was 10 µM and methotrexate (MTX) was 
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used as a negative control at a final concentration of 500 µM. All samples tested 
contained DMSO at final concentration of 0.5% v/v. 
The T. brucei growth assay was performed under the supervision of Dr. Kyu 
Joon Lee, a postdoc in the lab of Dr. Ziyin Li from McGovern Medical School, 
UTHealth. A stock of T. brucei blood-stream form (bsf) was cultured in HMI-9 
medium supplemented with 10% fetal bovine serum at 37°C with 5% CO2, in a sterile 
culture bottle and the medium was replenished every 2 days. To test the effect of the 
13 molecules, the stock culture was diluted down to an initial target concentration of 
5x104 cells/mL by counting cells using a hemocytometer. Experimental cultures were 
made in 48-well culture plates at a final volume of 200 µL. Each of the 13 molecules 
were added to different wells with MTX serving as the negative control. All the 
compounds were at the final concentration of 10 µM and contained DMSO at a final 
concentration of 0.5% v/v. Cultures were grown for 4 days and 10 µL of cells were 
removed and counted using a hemocytometer every 24 hours.  
 
2.6 Protein Purification 
Expression vector pET22b (+)-yDUT1 with 6X affinity His-tag was acquired 
from Addgene (plasmid #12667). The plasmid was purified using QIAprep Spin 
Miniprep Kit and transformed into BL21(DE3) competent cells for overexpression. 
For cloning of hDUT and tbdUTPase sequences, pET22b (+)-yDUT1 was first cut 
with NdeI and XhoI to remove the yDUT1 sequence. The hDUT sequence was PCR 
amplified using F primer: TAAGCACATATGCCATGTAGTGAAGAGAC and R primer: 
TGCTTACTCGAGATTTTTGCCGGTACTACC. The tbdUTPase sequence was PCR 
amplified using F Primer: TAAGCACATATGAAAAACGCGCGTCGTG and R primer: 
TGCTTACTCGAGACTCTTCAACCAGTGACC. The amplified PCR products were 
ligated to NdeI/XhoI cut pET22b (+)-yDUT1. Both ligations were confirmed by 
sequencing (Eurofins Scientific) using T7 and T7term primers, followed by 
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transformation into BL21(DE3) cells for overexpression. For a negative control, 
empty vector pRS426 was transformed into BL21(DE3) competent cells.  
 
Protein purification was performed as described previously in Dabrowski and 
Ahring (2003), [38], with some modification as described below. All four BL21(DE3) 
cell types were grown overnight in 5 mL of LB-ampicillin. Subcultures were then 
started in 500 mL of LB-Ampicillin-0.1% Glucose media and growth was monitored 
until an OD600nm of 0.3-0.5 was reached. IPTG was added at a final concentration of 
0.5 mM and cultures were grown for an additional 4 hours. The cells were harvested 
by centrifugation at 4,000 x g for 10 minutes at 4°C and the supernatant was 
removed, and the cells were stored in -80°C. Overexpression was confirmed by 
collecting cells before and after IPTG induction and Western immunoblotting was 
performed on the whole cell extracts. Thawed frozen cells were resuspended in 20 
mL of Buffer A (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 5 mM Imidazole, 0.1% Triton 
X-100, Protease Inhibitor Cocktail II, EDTA Free (10X)) and then sonicated for a total 
of 12 minutes (2 seconds on/off). They were then centrifuged at 18,000 x g for 20 
minutes at 4°C and lysate was collected along with a small 50µL aliquot and stored 
in 4°C. 2 mL of HisPur Ni-NTA Resin (Thermo Scientific, Prod # 88221) was added 
to the cell lysate and mixed overnight at 4°C. The column for protein purification was 
set up and lysates containing Ni-NTA resin was added to the column and the flow 
through was collected. Small 50 µL aliquots were collected from the flow through as 
well. The Ni-NTA resin was washed with 30 mL of Buffer A-50 (Buffer A with 50 mM 
imidazole) and 30 mL of Buffer A-80 (Buffer A with 80 mM imidazole) and lastly 
eluted with 10 mL of Elution Buffer (Buffer A with 500 mM imidazole). 50 µL aliquots 
also collected after the two wash steps and the elution was collected in 1 mL 
aliquots. The purity was checked by electrophoresis of all collected aliquots and 
elution through a Novex WedgeWell 4-20% Tris-Glycine Gel (Thermo Scientific) and 
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staining with EZ-RUN Protein Gel Staining Solution (Fisher Scientific, Prod # 
BP3620-1). Elution tubes 7-10 were combined and desalted with an Amicon Ultra-4 
10K Centrifugal Filter (Millipore, Prod # UFC801008). Then the purified protein was 
resuspended in Storage Buffer (20 mM Tris-HCl pH 8.0, 50 mM KCl, 50% Glycerol, 
0.5 mM PMSF) and stored at -80°C until it was ready for use. Protein quantification 
was performed via QuantiChrom Protein Assay Kit (BioAssay Systems, Prod # 
QCPR-500) with BSA as a standard.  
 
2.7 Western Immunoblotting 
 dUTPase protein levels were visualized by Western immunoblot of the crude 
cell lysates. Cells were first adjusted to an appropriate OD600nm and the cell pellets 
were resuspended in 100 µL of dH2O and 100 µL of 0.2 M NaOH and incubated at 
room temperature for 5 minutes. Cells were centrifuged and resuspended in 50 µL of 
SDS sample buffer and heated for 5 minutes at 95°C. All samples and the protein 
ladder (Xpert 2 Prestained Protein Marker) were loaded in volumes of 10 µL in 
Novex WedgeWell 10% Tris-Glycine Gel and initially run at 90 V for 10 minutes 
followed by 150 V for 30 minutes in SDS Running Buffer. The proteins were 
transferred from the gels to PVDF Membrane using Semi-Dry Transfer. All 
membranes were blocked with 5% milk in 1X TBS + 0.1% Tween overnight at 4°C. 
The primary and secondary antibody treatments were also performed overnight at 
4°C. Anti-Flag antibody treatment did not require a secondary antibody treatment, 
since it was conjugated with horseradish peroxidase (HRP). Anti-Nsr1 and Anti-His 
antibody treatments required a secondary antibody treatment of Anti-Mouse-HRP. 
For blot visualization, blots were treated with West-Q Femto ECL Solution for 3 




2.8  Pyrophosphate-based Enzymatic Activity 
 Enzymatic activity was measured using the PiPer Pyrophosphate Assay Kit’s 
“Measuring Enzymatic Activity” protocol (Thermo Scientific, Prod # P22062). For the 
three purified proteins, yDut1, hDUT, tbdUTPase, and our vector control, 500 ng was 
used for each purification and dUTP was used at a concentration of 0.5 mM. 
Fluorescence was measured using the BioTek Synergy Plate Reader at excitation 
and emission wavelengths of 575/15 and 620/15 nm respectively. Readings were 
recorded everyone and a half minutes for one hour at a temperature of 37°C.  
 
2.9 PCR-based Enzymatic Activity  
 A mix of individual dATP, dCTP, and dGTP and either dTTP or dUTP were 
utilized for PCR reactions. 5 µL of 5 mM dUTP or dTTP were incubated for 24 hours 
at 37°C with 5 µL of each purified protein; yDut1, hDUT, tbdUTPase, and vector 
control in 10 µL of reaction buffer (100 mM Tris-HCl pH 7.5, 20 mM MgCl2, 20 mM 
DTT, and 0.2 mg/mL BSA). The reactions were stopped by freezing and storing 
samples at -20°C. PCR reactions were set up utilizing Taq DNA Polymerase (Fisher 
Scientific, Prod # FB-5000-50) and MyTaq DNA Polymerase (Bioline, Prod # BIO-
21105) using the reaction concentrations according to the manufacturer’s 
recommendations. In place of a dNTP mix, dUTP or dTTP treated with yDut1, hDUT, 
tbdUTPase, or the vector control was added to the mix of dATP, dCTP, dGTP at 2 
mM each. PCR cycles were set as follows: 1 cycle of 95°C for 5 minutes, 35 cycles 
of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute,1 cycle of 72°C 
for 7 minutes, and hold at 4°C. PCR products were separated on 1% agarose gels 
and visualized using the Bio-Rad ChemiDoc MP Imaging System.
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Chapter 3: Results 
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3.1 Auxin growth assay/curves showing growth inhibition in the presence of 
auxin 
 The overall objective of this project was to discover a small molecule that 
binds and inhibits the function of T. brucei dUTPase but has no effect on human DUT 
or yeast Dut1. Since the dUTPase enzyme is essential for cell viability in T. brucei as 
well as in humans, a small molecule with such discriminatory properties will have a 
great potential as an anti-parasitic drug to combat African sleeping sickness. To 
accomplish this goal, I proposed: 1) to determine if the dUTPase proteins from 
human and T. brucei can functionally complement the absence of Dut1 in S. 
cerevisiae, and 2) to discover and characterize a list of possible small molecules that 
inhibit the function of T. brucei dUTPase. 
As described in Chapter 1, the dUTPase enzyme is essential in all organisms, 
making it an excellent target for a small molecule to bind to and inhibit its function, 
ultimately killing its host organism. Being able to use yeast a model system to 
express human and T. brucei dUTPase genes would allow us to screen for a drug or 
small molecule and achieve our overall objective. I hypothesize that this is possible 






Figure 4: dUTPase crystal structures.  
(A)yDut1 [24], (B)hDUT [35], and (C)tbdUTPase [25] 3D crystal structures. yDut1 
and hDUT are homo-trimers formed by beta-sheets, whereas tbdUTPase is a homo-
dimer formed by alpha-helices.  
S. cerevisiae dUTPase 
(Dut1) 
A 
Human dUTPase  
(Dut) 
B 




Furthermore, because dUTPase is essential, conventional null mutation 
methods are not feasible to study this enzyme. Here, I used in the budding yeast, S. 
cerevisiae, a conditional knockdown method known as the auxin inducible degron 
(AID) system. The strain YNK425, which contains the DUT1 gene with C-terminally 
located AID-tag (ydut1-AID), was created by a previous lab member, Dr. Norah Owiti. 
This allows us to utilize the AID system to knockdown the dUTPase enzyme in the 
presence of auxin. The effectiveness of the AID system was shown in numerous 
ways. First, a simple CFU assay was performed to show that in the presence of 
auxin at a concentration of 5 and 50 µM, the survival rate for YNK425 is reduced in 
comparison to two isolates of YNK421 (WT yDUT1) (Table 2). Survival rates were 
calculated relative to the cultures grown without auxin. Overall, auxin does not inhibit 
the growth of YNK421, but does indeed inhibit the growth of YNK425. Cell growth 
was maximally inhibited when cells are grown in the presence of 50 µM auxin. 
Although there are some cultures/replicates that had a high survival rate for YNK425, 
similar to when treated without auxin, the overall trend remained the same where the 
strain’s survival decreased in the presence of auxin. These replicates with outlying 






















WT DUT1 145 186 331 98% 
WT DUT1 212 151 363 86% 
WT DUT1 185 174 359 114% 
WT DUT1 209 177 386 97% 
WT DUT1 140 162 302 78% 
WT DUT1 166 142 308 87% 
ydut1-AID 188 179 367 120% 
ydut1-AID 12 9 21 58% 
ydut1-AID 5 15 20 91% 
ydut1-AID 42 38 80 29% 
ydut1-AID 50 47 97 41% 
ydut1-AID 41 40 81 30% 
50 µM 
WT DUT1 161 158 319 95% 
WT DUT1 198 195 393 93% 
WT DUT1 137 179 316 100% 
WT DUT1 162 175 337 84% 
WT DUT1 165 214 379 98% 
WT DUT1 184 201 385 108% 
ydut1-AID 152 152 304 99% 
ydut1-AID 2 2 4 11% 
ydut1-AID 1 5 6 27% 
ydut1-AID 9 15 24 9% 
ydut1-AID 38 46 84 35% 




To further show that the AID system is functioning properly, the strain YNK684 
(ydut1-AID ung1Δ) was also grown in the presence and absence of auxin. In YNK684 the, 
UNG1 gene encoding the uracil DNA glycosylase is deleted, thus the uracil in the DNA is no 
longer removed and AP sites are not generated. Therefore, it is expected that in YNK684, the 
increase in the level of uracil in DNA when Dut1 is degraded by auxin would have less effect.  
YNK684 was grown and treated with 50 µM or 100 µM auxin and subjected to the CFU assay 
(Table 3). Survival rates were calculated relative to the cultures grown without auxin. As can be 
seen in the table, all replicates for both isolates for YNK684 show a high survival rate in the 
presence of both 50 µM and 100 µM auxin, whereas YNK425 shows a low survival rate for both 
auxin concentrations. For both strains there are replicates that are outliers and do not follow the 
expected trend for their respective strains, which again is most likely due  
to suppressor mutations.  However, for YNK684, where a 56.00% survival rate is seen for 
YNK684 in 100 µM auxin, the outliers may be due to technical errors when preparing cultures 
resulting in low colonies formed. The dashes in the table represent no colonies were grown in 
the plate. Therefore, in the cases in which one of the plates did not have any colonies, the 































Count Survival Rate 
50 uM Auxin 
ydut1-AID - 7 14 6.73% 
ydut1-AID 15 20 35 16.36% 
ydut1-AID 9 5 14 5.17% 
ydut1-AID 24 24 48 21.05% 
ydut1-AID 14 6 20 8.20% 
ydut1-AID 23 23 46 22.01% 
ydut1-AID 9 9 18 7.76% 
ydut1-AID 106 89 195 87.05% 
ydut1-AID 21 5 26 13.27% 
ydut1-AID 22 17 39 18.57% 
ydut1-AID ung1Δ 76 108 184 88.46% 
ydut1-AID ung1Δ 125 68 193 96.50% 
ydut1-AID ung1Δ 108 109 217 93.94% 
ydut1-AID ung1Δ 113 101 214 91.45% 
ydut1-AID ung1Δ 154 112 266 105.14% 
ydut1-AID ung1Δ 118 118 236 112.38% 
ydut1-AID ung1Δ 141 107 248 124.00% 
ydut1-AID ung1Δ 99 96 195 100.00% 
ydut1-AID ung1Δ 154 117 271 115.81% 
ydut1-AID ung1Δ 106 88 194 79.51% 
100 uM Auxin 
ydut1-AID 5 11 16 7.69% 
ydut1-AID 9 22 31 14.49% 
ydut1-AID 7 15 22 8.12% 
ydut1-AID 18 21 39 17.11% 
ydut1-AID 16 9 25 10.25% 
ydut1-AID 13 18 31 14.83% 
ydut1-AID 18 14 32 13.79% 
ydut1-AID 115 87 202 90.18% 
ydut1-AID 11 9 20 10.20% 
ydut1-AID 23 17 40 19.05% 
ydut1-AID ung1Δ 89 114 203 97.60% 
ydut1-AID ung1Δ 95 98 193 96.50% 
ydut1-AID ung1Δ 88 81 169 73.16% 
ydut1-AID ung1Δ 106 84 190 81.20% 
ydut1-AID ung1Δ 94 112 206 81.42% 
ydut1-AID ung1Δ - 102 204 97.14% 
ydut1-AID ung1Δ 56 56 112 56.00% 
ydut1-AID ung1Δ 111 74 185 94.87% 
ydut1-AID ung1Δ 120 108 228 97.44% 
ydut1-AID ung1Δ - 123 246 100.82% 
“-“ represent no colonies were grown 
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The CFU assay shows that the AID system in the strain YNK425 is functional 
and effective in conditionally knocking down the essential enzyme Dut1 in S. 
cerevisiae. However, due to inconsistencies with the CFU assay in terms of colony 
counting and survival rates, the effectiveness of the AID system in YNK425 was also 
examined using the spot growth assay (Figure 5) and growth curves determined by 
using a plate reader (Figure 6). In Figure 5, four different auxin concentrations were 
tested on YEPD plates; 0, 50, 100, and 500 µM. The growth of ydut1-AID-containing 
YNK425 is significantly inhibited as the auxin concentration increases due to the 
presence of the AID system causing the degradation of yDUT1. Conversely, the wild-
type yDUT1-containing strain YNK421 shows no reduction in growth under any of the 
auxin concentrations. The smeared culture on the 0 µM auxin plate for YNK425 was 
due to a pipetting error. Figure 6 also includes the strain YNK679 (ydut1-AID-ung1Δ), 
which is expected to show no signs of growth inhibition, because although grown in the 
presence of auxin, AP sites do not form due to the absence of UNG1. The growth curves 
shown in Figure 6 consist of YNK421, YNK425, and YNK679 incubated in YEPD and at three 
different auxin concentrations (0, 50, and 500 µM). When YNK425 is treated with 50 µM or 500 
µM auxin, there is a significant inhibition in the growth rate in comparison to when YNK425 is 
not treated with auxin. In addition, YNK421 and YNK679 grow to a saturation point as expected 
with and without auxin. It can be noted that YNK425 does not grow as well as the other two 
strains even in absence of auxin. This may be because the AID-tag may slightly interfere with 
Dut1 function.  
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Figure 5: Spot growth assay with and without auxin. 
Cultures for strains ydut1-AID and WT yDUT1 were serially diluted and spotted on 
YEPD plates containing 0 µM (top left), 50 µM (top right), 100 µM (bottom left), and 
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Figure 6: Growth curves showing effectiveness of AID system. 
OD600nm measurements over indicated time in hours for YNK421, YNK425, and 
YNK679 in the presence of 0, 50, and 500 µM auxin in YEPD media utilizing BioTek 


























After observing growth inhibition of YNK425 in the presence of auxin, we next 
wanted to confirm the AID system’s specificity and visually demonstrate the auxin-
dependent degradation of the Dut1 protein. Since the Dut1 protein is 3X-Flag tagged 
in addition to the AID tag in YNK425, visualization of its degradation in the presence 
of auxin is made possible using Western immunoblotting with anti-Flag antibody. 
Subcultures of YNK425 were started and initially grown for 4 hours before adding 
auxin to have an equal Dut1 expression level for cultures treated with and without 
50µM auxin. Growth measurements at OD600nm were also recorded to ensure the 
same number of cells were loaded onto the gels for each timepoint to track the 
degradation of Dut1 in the strain YNK425 (Figure 7). Cells were collected and 
extracts were prepared at 0, 2, and 6 hour timepoints. It can be clearly seen that 
after 2 hrs of treatment with 50 µM auxin, the amount of Dut1 protein is greatly 
reduced, but recovers at 6 hours. Without any auxin, the expression of Dut1 does not 





                     
                     
 
Figure 7: Degradation of Dut1 in YNK425. 
Cell extracts were collected at 0, 2, and 6 hour timepoints to create a western blot 
showing the degradation of Dut1 when treated without auxin (left) or with 50 µM 
auxin (right). 3X-Flag tagged ydut1-AID was detected using anti-Flag antibody. Anti-






























Time (hours)       0                    2                  6       0                    2                  6 
0 µM Auxin 50 µM Auxin 
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The auxin CFU assay, spot growth assay, and growth curves that have been 
presented all prove that the AID system is indeed functional in the strain YNK425 
and effectively degrades the dUTPase protein in the thymidine synthesis pathway. 
Since this pathway is heavily targeted by well-studied molecules such as 5-FU 
(Figure 8A), we then sought to see how YNK425 behaves in the presence of auxin 
as well as 5-FU. This experiment was conducted to determine whether the 
combination of 5-FU and auxin would have a synergistic effect on the cell growth in 
YNK425 due to an increase in [dUTP/dTTP] (Figure 8B). This was tested with 
another growth curve analysis using a plate reader. The auxin concentrations used 
for this were 0, 5, and 500 µM along with and without 25 µM 5-FU. Initially, 10 µM of 
5-FU was used, but the difference in cell growth was less than significant (data not 
shown). It can be seen that when 25 µM 5-FU is added to 0 µM and 5 µM auxin, you 
do see an additive effect in cell growth inhibition is observed. However, at 500 µM 
auxin there is less cell growth with 5-FU added, but the difference is too small to 
make any significant conclusion. Overall, it can be stated that auxin in combination 












Figure 8: dTTP synthesis pathway and the targets of auxin, 5-FU, and MTX. 
(A)5-FU and MTX are well known drugs that target thymidylate synthetase and 
dihydrofolate reductase, respectively, in the thymidine synthesis pathway. (B) 
Growth curve of YNK425 with and without auxin and 25 µM 5-FU, grown in YEP-GE 


















YNK425 0μM Auxin + 
25μM 5-FU
YNK425 5μM Auxin + 
25μM 5-FU






















3.2 Expression of human and T. brucei dUTPase in yeast  
With the overall objective being to discover a small molecule that inhibits 
tbdUTPase, next I tested if dUTPase genes from yeast, human, and T. brucei on 
plasmids under a galactose inducible promoter could be transformed into YNK425 
and compliment the low level of dUTPase when the native Dut1 protein is 
conditionally knocked down in the presence of auxin. Table 4 below shows the 
sequences used for yeast, human, and T. brucei dUTPase genes. The sequences 
also contain a HA tag which allowed for their expression to be confirmed. This was 
performed by a previous graduate student, Dr. Norah Owiti. The plasmid structure 
containing dUTPase genes is shown in Figure 9.  
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Figure 9: General structure of plasmids containing yeast, human, and T. brucei 
dUTPase genes. 
The dUTPase genes are under the control of a galactose inducible promoter and 
also contain a 3X-HA tag. The inducible promoter allows for controlling its 
expression and the HA tag allows for monitoring said expression. The plasmids also 









or T. brucei) 
pGal 
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Plasmids containing vector control, yDUT1, hDUT, and tbdUTPase were 
purified and then transformed into YNK425 using standard lithium acetate (LiAc) 
yeast transformation protocol and selected for on SD-URA plates. Appropriate 
colonies were selected to test for the functional complementation of yDUT1, hDUT, 
and tbdUTPase using two assays: CFU assay and growth curves (Table 5 and 






Table 5: CFU assay of YNK425 transformed with vector, yDUT1, hDUT, and 
tbdUTPase plasmids. 
CFU Assay (50 µM Auxin) 
Plasmid Vector yDUT1 hDUT tbdUTPase 





Figure 10: Assay testing functional complementation following yeast 
transformation. 
Growth curve of YNK425 transformed with vector, yDUT1, or hDUT plasmids grown 
in SD-URA 2% galactose/raffinose media with the addition of indicated concentration 





























In Table 5, yDUT1, hDUT, and tbdUTPase plasmids transformed into YNK425 
in the presence of auxin are expected to have significantly higher survival rates than 
the vector. However, the vector plasmid transformation shows the highest survival 
rate when the transformants are grown in the presence of 50µM auxin. The data 
shown in Table 5 is just one of the several trials that was performed. All had the 
same results where the cell survival of vector transformed YNK425 was not different 
or was better from the other three plasmids in presence of 50 µM auxin. Due to 
inconsistencies that have been observed before with the CFU assay, the 
transformants were tested by generating growth curves using the plate reader. 
Figure 10 does not have data for tbdUTPase transformants in YNK425 because of 
the low number of colonies formed, which was not sufficient enough to create a 
growth curve. Therefore, I proceeded to use only vector, yDUT1, and hDUT 
transformants. All cultures were initially diluted to 0.1 OD600nm to start with an equal 
number of cells. The SD-URA 2% galactose/raffinose medium was used which 
resulted in a low max OD600nm of approximately 0.5. The growth of transformed cells 
was measured in three different auxin concentrations, 0, 50, and 500 µM. In the 
presence of 50 or 500 µM auxin, cells transformed with the vector control was 
expected to show a significant inhibition in growth rate because of the degradation 
on the native Dut1 with no other dUTPase to complement its loss. However, we 
observed that the vector control-transformed cells at both concentrations of auxin 
grows almost similar to vector control with no auxin as well as the yDUT1- or hDUT-
transformed cells. Both the CFU assay and growth curve analysis were performed 
several times giving the same result. To combat this, a few changes were attempted 
including using a commercially available SC-URA amino acid mix (Sunrise Science 
Products; Prod 1306-030), using YEP-GE 2% galactose media instead of using SD-
URA 2% galactose/raffinose media, and instead of an ethanol-soluble auxin, using a 
water-soluble auxin. All these changes resulted in the same outcome with 
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complementation not being able to be proven, due to no cell growth inhibition 
observed in cells transformed with the vector control (data not shown). 
In an alternative approach to the plasmid transformation, we moved on to 
integrating the dUTPase protein-expressing cassette into the yeast genome.  A 
proper locus to integrate the dUTPase genes into the yeast genome would be where 
normal yeast functions would not be disrupted by the integration. In Dr. Kim’s lab, all 
of the yeast strains being used are MATa haploid strains, therefore genes involved in 
mating functions are considered to be neutral or non-functional genes. One such 
gene is the HO gene, encoding an endonuclease necessary for mating type 
switching from MATa to MAT! and vice versa [39]. In order to incorporate hDUT and 
tbdUTPase into the HO gene, the previously used plasmids consisting of hDUT and 
tbdUTPase were modified to included sequences from the HO gene upstream and 
downstream of pGal and URA3 marker along with NotI restrictions sites to cut out the 
desired region of the modified plasmid. The modified fragments were transformed 
into the strain YNK425 and were integrated into the yeast genome via homologous 
recombination.  
The hDUT and tbdUTPase genes incorporated into the yeast genome are HA 
tagged. Therefore, I first checked to see if these proteins were properly expressed in 
YNK425 by Western blotting with anti-HA antibody (Figure 11). Both hDUT and 
tbdUTPase proteins are well expressed when grown in YEP-GE 2% galactose media 
in comparison to just YEP-GE media, in which they should not be expressed due to 











                                     
                                      
Figure 11: Western blot showing expression of HA tagged hDUT and tbdUTPase 
proteins. hDUT (top) and tbdUTPase (bottom) genes were integrated into the yeast 
genome at the HO locus followed by Western blots to confirm expression. The new 
strains were grown in YEP-GE 2% galactose media allowing for their expression. 
Bands for tbdUTPase are shown white when the image was captured because the 
gel was overloaded with the extract collected. Bands present below tbdUTPase is 
most likely the degraded tbdUTPase protein. 
 
After confirming expression, next I tested if the dUTPase genes integrated into 
the yeast genome in the strain YNK425 would give the expected results: when grown 
in YEP-GE with auxin both strains with hDUT and tbdUTPase should show significant 
inhibition of growth because the endogenous yDUT1-AID will be degraded and 
galactose is not present to induce the expression of hDUT and tbdUTPase. 
Inversely, when grown in YEP-GE 2% galactose media with auxin the strains should 
exhibit no inhibition in growth, because although auxin’s presence causes the 
endogenous yDut1-AID to degrade, the expression of hDut and tbdUTPase is 
induced due to the presence of galactose ultimately showing functional 
complementation. Functional complementation of these new strains was tested by 
creating growth curves (Figure 12). The following statements about Figure 12 apply 
to both hDUT (top graph) and tbdUTPase (bottom graph). When ydut1-AID strain 
(YNK425) is treated with 500 µM auxin in both YEP-GE and YEP-GE-galactose 
(YEP-GE-Gal) the growth is significantly inhibited as expected. When human and T. 
brucei dUTPase genes were added and grown in YEP-GE, they do not show any 


















behave similarly to YNK425 since galactose is not present to induce the expression 
of the dUTPase gene. When grown with galactose in the presence of auxin, the 
strain grows similarly to when auxin is not present, which suggests that the human 
and T. brucei dUTPase genes may be able to functionally complement when the 
native yDut1-AID is degraded. However, since the new strains did not have growth 
inhibition in the presence of auxin when grown in only YEP-GE, that functional 













Figure 12: Growth curves testing functional complementation of hDUT and 
tbdUTPase genes integrated into the yeast genome in the HO gene.  
hDUT (top) and tbdUTPase (bottom) genes were integrated into the yeast genome 
and tested for functional complementation in the presence of galactose and 500 µM 



































































To check if the result shown in Figure 12 is possibly functional 
complementation, a negative control was created that mimicked the integration of a 
dUTPase gene into the HO locus. For the negative control, the same plasmid 
consisting of tbdUTPase under the control of pGal, a URA3 marker, and flanking HO 
sequences was cut using the restriction enzyme SpeI. Within the tbdUTPase 
sequence, SpeI is capable of cutting at two locations, which allowed a significant 
portion of the gene to be removed and the plasmid was religated, creating a plasmid 
containing an inactive tbdUTPase gene. This plasmid was transformed into YNK425 
and the addition of the inactive tbdUTPase gene into the HO gene was confirmed 
with PCR (data not shown). The growth of this new strain, YNK760 (now referred to 
as ‘Neg’ for negative control) was tested by creating growth curves (Figure 13). The 
Neg strain was grown alongside YNK425 and is expected to grow similarly to it in 
both YEP-GE and YEP-GE with galactose in the presence and absence of 500 µM 
auxin. In both mediums, we observed that, when Neg is grown with 500 µM auxin, it 
does not show any signs of growth inhibition. Because we failed to demonstrate the 
growth inhibition of the Neg strain in the presence of auxin, we do not have the 
proper control to demonstrate that the expression of hDUT and tbdUTPase in the 
presence of galactose could be complementing the absence of the native yDut1.  
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Figure 13: Growth curves showing growth behavior of inactive tbdUTPase 
integrated into the HO gene.  
YEP-GE (top) and YEP-GE with galactose (bottom) mediums were used to grow 
YNK425 and Neg strains with and without 500 µM auxin. Inactive tbdUTPase gene 










































This outcome led us to question whether or not the endogenous yDUT1-AID 
was being degraded in these newly created strains with new dUTPase genes. Similar 
to Figure 7, Western blots were carried out to monitor the degradation of the 3X-Flag 
tagged ydut1-AID (Figure 14). Two sets of cell extracts were collected at three 
timepoints, 0, 1, and 2 hours, one set without auxin and the other with 500 µM auxin. 
As shown in Figure 15, over the course of the two hours, the endogenous ydut1-AID 
protein in the original YNK425 degrades in the presence of auxin. However, in 
strains with the integration of hDUT, tbdUTPase, or Neg cassette at the HO locus, 
the endogenous ydut1-AID is not degraded when treated with 500 µM auxin. The 
integration of the dUTPase sequences into the yeast genome seems to somehow 
interfere with AID system, no longer allowing for ydut1-AID to be degraded. Overall, 
the methods and experiments mentioned here were not able to prove 
complementation did in fact occur. Therefore, other experiments were conducted as 





                             
                             
 
 
Figure 14: Western blot tracking the degradation of endogenous ydut1-AID. Cell 
extracts were collected at 0, 1, and 2 hour timepoints to create a Western blot 
showing the degradation of the 3X-Flag tagged endogenous yDut1 when treated 
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3.3 High throughput virtual screen for T. brucei dUTPase ligands using 
Schrödinger’s suite  
Significant structural differences exist between human and T. brucei dUTPase 
proteins suggesting that it would be feasible to find a small molecule inhibiting the 
function of T. brucei dUTPase with little effect on human dUTPase. Since we were 
not able to set up complementation system using S. cerevisiae as a model system, 
which would have been a necessary tool in screening for such small molecule in 
vivo, an alternative method to perform a drug screen is a virtual or computational 
approach. This component of the project was made possible thanks to the 
collaboration with Dr. John Tainer at MD Anderson Cancer Center who provided us 
access to the software and the virtual drug screen was performed by Dr. Nayun Kim. 
With crystal structures available online from other studies of human and T. brucei 
dUTPases, a virtual drug screen was performed utilizing Schrödinger’s Suite. Being 
able to conduct a virtual drug screen rather than a physical one in multiple-well 
plates is a much faster and efficient process, allowing for thousands of small 
molecules available online to be tested with the protein of desire [33]. In our case, 
we know the best fitting molecule that binds to the binding pocket of the dUTPases is 
dUTP/dUMP (Figure 15). Therefore, small molecules that are similar in structure to 
dUTP/dUMP would be the best candidates for the purpose of this project.  
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Figure 15: T. brucei dUTPase residues interacting with dUMP. 
This interaction map was generated using PyMol software. dUTPase cleaves off a 
pyrophosphate from dUTP, leaving behind dUMP, which can be used in the 




To begin the virtual screen, ligands to be screened needed to be narrowed 
down from the thousands available through the online database. Our goal was to 
identify a small molecule that binds to T. brucei dUTPase to inhibit its function but 
does not bind to human dUTPase.  For the HTVS, a custom library of 5000 
compounds (called “Tainer 5000”) was selected from the Life Chemical library based 
on their variety, low toxicity, small molecular weights, and drug-like properties.  This 
library was generated by the lab of John Tainer at MD Anderson to use in screening for 
ligands that bind to DNA or nucleotide-interacting proteins.  Once molecules that bind 
to T. brucei dUTPase have been found, they can then be tested to see which ones 
do not fit the human dUTPase, which is what we desire. The 1.47 Å resolution T. brucei 
dUTPase structure (PDB ID: 4DK2) [25] was uploaded to the Glide program. In order to 
screen for ligands that bind to the catalytic pocket of dUTPase, the “Search Space” was 
defined as the annotated catalytic center where dUTP/dUMP binds. The dUTPase requires 
a magnesium cation (Mg 2+) to be enzymatically active [40]. Several charged residues 
(Q21, N25, E48, E51, R215, K227) involved in hydrogen bonding with PO4 and Mg2+ are 
located in the catalytic core in addition to several aromatic residues (W41, T76, H82, F83, 
Y220). For the virtual screen, the software allowed us to also include magnesium with 
the dUTPase crystal structure to have a more accurate representation of the protein. 
One caveat of performing a drug screen in this manner is the crystal structure of our 
target protein is in a static state, whereas proteins are always in a dynamic state, 
which may lead to more molecules being predicted to be positive hits in the screen 
[41].  
From the virtual docking simulation of the Tainer 5000 library to the catalytic 
pocket of TbdUTPase, over 1000+ molecules were predicted as positive hits 
(docking score <-6.5; MMGBSA dG bind <-20) (Figure 16). These molecules were 
plotted as docking score vs. MMGBSA dG Bind. The docking score indicates how 
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well the molecule binds or fits into the binding pocket of the protein structure in 
question. The MMGBSA dG Bind can also be referred to as “free energies of 
binding”, which indicates how strong of a bond there is between the molecule and 
protein structure in question. In addition, the measurements are in log scale, 
therefore, the more negative the values are for a molecule, the better it fit into the 
binding pocket with a greater binding strength. The virtual docking of Tainer 5000 
library was repeated using the annotated structures of human DUT (PDB ID: IQ5U and 3ARA) 
[35, 36].  From the positive hits from docking to the tbdUTPase structure, we eliminated any 
positive hits to the hDUT in order to find a ligand specific to tbdUTPase but not to hDUT.  The 
list was narrowed down to 13 molecules by 1) prioritizing lower MMGBSA dG Bind 
and docking score, 2) selecting only one among ligands with very similar structures, 
and 3) prioritizing molecules with structural similarity to nucleotides (Table 6).  
These 13 molecules were provided to us by Dr. John Tainer. Among the 13 
molecules, only one had been previously characterized as a drug, #7, 
carbamazepine. This is a common anticonvulsant drug that is widely used to control 
seizures [42]. Anticonvulsants are commonly used for brain disorders [43], thus must 
penetrate into the blood-brain barrier in order to be effective. Since T. brucei 
infection at its second stage does get into blood-brain barrier as well, carbamazepine 
is a well-suited molecule to potentially target and inhibit the function of T. brucei 
dUTPase regardless of the stage of the disease. Carbamazepine also is a well-
studied drug and therefore would not require more studies such as toxicity analysis. 
With 13 candidate molecules finalized, these molecules can now be further used to 





Figure 16: HTVS result showing positive binding hits for T. brucei dUTPase. 
This figure shows the results of the HTVS. T. brucei dUTPase was tested with the 
presence of magnesium. The y-axis, docking score, indicates how well ligands fit into 
the binding pocket of the structure and the x-axis, MMGBSA dG Bind, indicates how 










Table 6: 13 molecules narrowed down by HTVS. 
Molecule # ID Number Name Structure 
1 F2147-0060 5-(aminomethyl)-3-(4-methylphenyl)-1,3-oxazolidin-2-one 
 
2 F2162-0006 [5-(4-fluorophenyl)-1,2-oxazol-3-yl]methanamine 
 
3 F1905-0500 3-amino-1,2,3,4-tetrahydronaphthalen-2-ol 
 
4 F2189-0253 2-[2-(3-fluorophenyl)-[1,3]thiazolo[3,2-b][1,2,4]triazol-6-yl]ethanamine 
 







7 F0348-2551 Carbamazepine 
 
8 F3385-1587 4-[4-(2-bromophenoxy)-1H-pyrazol-5-yl]benzene-1,3-diol 
 






Table 6. Cont.  
Molecule # ID Number Name Structure 
11 F0916-0420 2-(6-chloro-4-methyl-3,4-dihydro-1H-isoquinolin-2-yl)ethanol;hydrochloride 
 
12 F1364-0012 2-(1-benzhydrylbenzimidazol-2-yl)-1,3-benzoxazole 
 






3.4 T. brucei/yeast viability testing with molecules found from the high 
throughput virtual screen 
 With the 13 molecules found that virtually bind to T. brucei dUTPase, but not 
to human dUTPase, I next proceeded to see if any one of the molecules had a direct 
growth-inhibitory effect on T. brucei cells. Since these molecules likely bind to 
dUTPase, an essential enzyme, if one of them binds and inhibits the function of 
dUTPase in T. brucei, then those cells will no longer be viable and there should be a 
significant increase in cell death. I was taught by Dr, Kyu Lee, a postdoc in Dr. Ziyin 
Li’s lab, to grow cultures of T. brucei, so that I could perform these tests.  
A stock culture of a blood-stream form T. brucei was started and was 
replenished with fresh medium when the stock culture was nearing its saturation 
point (approximately every 2 days). All of the 13 molecules were dissolved in DMSO, 
therefore I first tested different percentages of DMSO, which would be used as a 
negative control, to see if they were toxic to T. brucei cultures. The optimal, non-
cytotoxic DMSO percentage to use for the cultures was determined to be 0.5% (data 
not shown). Final concentrations of 10 µM for the 13 molecules and MTX, which was 
used as a positive control since it inhibits the essential thymidylate synthesis 
pathway, were added to the T. brucei cultures. When diluting the molecules into the 
cultures, the concentrations of DMSO in the 48-well plate being used was 
approximately 0.3%, therefore, more DMSO was added to reach the final 
concentration of 0.5% to match the negative control. All cultures started with an 
initial concentration of 5x104 cells/mL and cells were counted daily for 4 days with a 
hemocytometer. Due to the great amount of time it would take to count all the cells 
for a total of 15 samples and risk of leaving T. brucei cultures out of the incubator 
too long, the molecules were split up into 4 different sessions (Figure 17). MTX 
treatment led to significant signs of cell death whereas the control, (ctrl in Figure 
17), showed normal growth. Of the 13 molecules, molecule #4 led to significant cell 
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death to the level similar to MTX-induced cell death. Molecule #5 showed a negative 
cell growth rate from day 3 to day 4, which may indicate a delayed effect of cell 
killing. Unfortunately, no other molecule showed any signs of growth inhibition. 
Molecule #4 may be able to kill T. brucei by binding to dUTPase and inhibiting its 
function, based on the virtual screen result.  
Next, I determined if molecule #4 is a generally toxic molecule and would be 
harmful to yeast cells. The same 13 molecules listed in Table 6 were tested on the 
yeast strain YNK421 with wild type DUT1 using the plate growth assay. I first 
determined what percentage of DMSO is safe to use for YNK421.  0.5% DMSO was 
determined to not affect cell growth of YNK421 (data not shown). The 13 molecules 
were again tested at the concentration of 10 µM but MTX this time was increased to 
500 µM because 10 µM of MTX did not sufficiently inhibit yeast cell growth. Due to 
space on the 96-well plate, the 13 molecules were split into two different plate reader 
runs (Figure 18). Molecule #4, which inhibited the growth of T. brucei, presumably 
by inhibiting the function of dUTPase, had no effect on the growth of yeast. From 
this, it can be concluded molecule #4 does not inhibit yeast dUTPase and therefore, 
it most likely would also have no effect of human dUTPase, which is highly 
homologous to the yeast protein.  And, molecule #5, which partially inhibited the 





Figure 17: Growth curves testing the effect of molecules 1-13 on T. brucei. 
T. brucei blood-stream form cultures were grown in triplicates testing the effect of 
molecules 1-13 on growth. All samples contain a final 0.5% DMSO and all molecules 
























































































Figure 18: Growth curves testing the effect of molecules 1-13 on YNK421. 
Growth curves were generated using a plate reader to test the effect of molecules 1-
13 on YNK421 growth. All samples contain 0.5% DMSO and all molecules were 
tested at a final concentration of 10 µM. 0.5% DMSO was the negative control and 





















































3.5 Overexpression and purification of yeast, human, and T. brucei dUTPase 
proteins 
 In order to test whether the candidate ligands found through HTVS would 
inhibit T. brucei dUTPase, but have no effect on human and yeast dUTPases, we 
overexpressed and purified the dUTPase enzymes to directly test the enzymatic 
activity in the presence of candidate molecules. Creation of plasmids containing 
hDUT and tbdUTPase and their transformation into BL21 cells, along with a vector as 
a control, is described under Protein Purification in the Materials and Methods. First, 
overexpression after adding IPTG was confirmed for all of the following proteins 
before proceeding to protein purification: yDUT1, hDUT, tbdUTPase #1, tbdUTPase 
#2, and vector (data not shown). Figure 19 shows the results of the protein 
purification process. For hDUT, tbdUTPase #1, and tbdUTPase #2, the proteins were 
overexpressed, and a large amount of purified protein was eluted. All bands for the 
purified proteins were the expected size: yDUT1 approximately 15 kDa, hDUT 
approximately 17 kDa, and tbdUTPase approximately 28 kDa. The purification of the 
vector does not contain any prominent bands. The other prominent bands that are 
present with hDUT and both tbdUTPase purifications could possibly be multimers of 
the proteins. yDUT1, hDUT, and tbdUTPase #1 were also sent for mass spectrometry 








Figure 19: Protein purification results of collected fractions and elution.  
Protein staining results for the collected fractions and elution of A) yDUT1, B) hDUT, 
C) tbdUTPase #1, D) tbdUTPase #2, and E) vector. 5µL of each sample was applied 
to the gel. The following states what each of the lanes represent. L: ladder, F1: cell 
lysate, F2: column flow through, F3: wash #1 with 50 mM imidazole, F4: wash #2 
with 80 mM imidazole, E1-E10: elution aliquots with 500 mM imidazole, F5: leftover 



















































 After the elution fractions were checked by electrophoresis and Coomassie 
Blue staining, elution fractions 7-10 from each purification were collected and 
combined for each. The combined fractions were then transferred to storage buffer 
and stored in 100 µL aliquots as described in the Materials and Methods section. 
Table 7 shows the concentrations of the purified proteins calculated using a protein 
quantification kit. Figure 20 shows the Coomassie-stained protein images of stored 
fractions. With this successful protein purification, these proteins’ enzymatic activity 





Table 7: Protein concentrations of purified proteins. 
Protein yDUT1 hDUT tbdUTPase #1 tbdUTPase #2 vector 
Concentration 




Figure 20: Final protein staining image of purified proteins. 
5µL of each final aliquoted protein was run, showing the degree of purity. The 
following states what each lane represents. Lane 1: yDUT1, Lane 2: hDUT, Lane 3: 
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3.6 Enzymatic activity of dUTPase proteins 
 I observed that T. brucei cells were killed in the presence of molecule #4, 
however, it was important to determine if the effect is due to specific inhibition of 
dUTPase activity. In order to address this, dUTPase proteins (yeast, human, and T. 
brucei) were purified. A protein extract from E. coli cells transformed with empty 
vector was subjected to the same purification protocol and serves as the negative 
control (referred to as “vector”).  dUTPase’s function is to convert dUTP to dUMP 
and, in that process, a pyrophosphate, PPi, is generated as a by-product. The 
generation of PPi can be measured to determine the enzyme’s activity. The PiPer 
Pyrophosphate Assay Kit measures the generation of PPi by first converting it to an 
inorganic phosphate, Pi. Pi can be detected in a series of reactions ultimately 
leading to the generation of resorufin, a redox probe, which emits a fluorescent 
signal that can be measured with a plate reader. Following the kit’s protocol, several 
runs were performed testing the enzymatic activity of the five purified proteins (Table 
8). The kit calls for generating a standard curve by making dilutions of the provided 
pyrophosphate standard and then back calculating the amount of pyrophosphate 
generated by the enzyme in question. Unfortunately, every time this assay was 
performed, the standard provided with the kit did not result in the appropriate 
fluorescent values to generate a proper linear curve and the amount of 
pyrophosphate generated could not be calculated. Furthermore, every time this 
assay was run, it seemed that yDut1 and hDUT were active enzymes but tbdUTPase 
#1 and #2 were not active. The tbdUTPase fluorescence values are not significantly 
different from the negative control. Thus, it appears that tbdUTPase is not 
enzymatically active. In addition, the vector’s fluorescence, which is expected to be 
similar to the negative control, was significantly lower. Due to the assay not working 
as expected, the purified proteins could not be tested to determine if molecule #4 
affects their activity.  
 67 
 
Table 8: PiPer Pyrophosphate assay experiment. 
Sample Fluorescence Standard Deviation 
PPi 100 µM 193.5 18.84 
PPi 50 µM 201 6.78 
PPi 25 µM 179 20.05 
PPi 12.5 µM 169.5 9.47 
PPi 6.25 µM 141.75 16.07 
PPi 3.125 µM 123.5 12.07 
Negative Control 92.25 0.96 
Positive Control 657.5 47.68 
yDut1 159.25 5.12 
hDUT 148.75 6.24 
tbdUTPase #1 88.5 3.42 
tbdUTPase #2 95.25 7.63 





The inconsistent results with the PiPer Pyrophosphate Assay Kit led me to use 
an alternate method to measure the enzymatic of dUTPase. It is well known dUTP 
(U) can be incorporated into DNA and dUTPase is responsible for inhibiting this by 
converting dUTP to dUMP. Based on this property, we used a PCR-based assay to 
test the activity of dUTPase and the effect of candidate molecules #4 and #5. When 
nucleotides dATP, dTTP, dCTP, and dGTP (A, T, C, and G) are used to form a PCR 
product, the PCR product can be visualized via gel electrophoresis. The same can 
be done by using nucleotides A, U, C, and G since U can be added to DNA in lieu of 
T. When a nucleotide is missing, then no PCR product will form because the 
amplification cannot occur completed without the missing nucleotide. When A, C, G, 
along with either T or U, are used for PCR and U has been incubated with a 
dUTPase before the reaction, U as dUTP will have been degraded to dUMP, which 
cannot be incorporated into DNA resulting in no PCR product formed. When T is 
incubated with dUTPase, it should have no effect on PCR efficiency since dUTPase 
is specific for U. PCR was performed using T7 (TAATACGACTCACTATAGGG) and 
M13Rev (CAGGAAACAGCTATGAC) primers and using pGPD2, an arbitrary plasmid, 
as a template. In addition, each PCR reaction contained 5 µL of purified dUTPase 
protein and 0.3% DMSO.  The PCR reactions were repeated with either Taq DNA 
polymerase or MyTaq DNA polymerase (modified and licensed product of Bioline). 
 Figure 21 shows the results of the PCR-based enzymatic activity assay. Both 
molecules #4 and #5 were tested. For either DNA polymerases used, the controls 
resulted in the proper PCR products forming as expected. Lanes 1 and 2 in both 
Figures 21A and 21B show a very prominent band forming when individual 
nucleotides are used and U incorporated into DNA can still form a PCR product. 
Lane 3 shows when missing a nucleotide, missing T/U, results in no formation of a 
PCR product due to incomplete PCR. Lanes 4-8 consist of T nucleotide incubated 
with water or one of the four purified proteins. For each lane a prominent band is 
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present as expected because dUTPase does not affect dTTP (T). In Figure 21B, 
bands in lane 5 are less visible when using MyTaq DNA Polymerase which may be 
due to pipetting error. Lane 9 is another control where U incubated with water should 
have no effect on PCR product formation. For Lanes 10 and 11 with DMSO only, 
yDut1 or hDUT should degrade dUTP leading to no PCR product formation. Similar 
results with no PCR product were expected when molecule #4 or #5 are added since 
these molecules are not expected to inhibit yeast or human enzymes.  For lane 12 
where dUTP was treated with TbdUTPase prior to PCR reaction, PCR product was 
either significantly reduced (with Taq polymerase) or absent (with MyTaq 
polymerase) indicating that tbdUTPase actively degraded dUTP. For the reaction in 
lane 12 in the presence of molecules #4 and #5, more prominent PCR products are 
expected if either of these molecules inhibit tbdUTPase, so that dUTP is not 
degraded to dUMP. However, as shown in in lane 12 of Figure 21A, PCR band is 
significantly less present for molecule #4 and not visible at all for molecule #5. For 
Figure 21B, bands are not present for both molecules #4 and #5 in lane 12. This 
indicates that molecules #4 and #5 may not be dUTPase specific and the killing of T. 
brucei cells exhibited in Figure 17 may be due to another pathway being affected. 
Lane 13 consisting of the vector control shows prominent bands present as expected 
due the absence of dUTPase proteins. Overall, the enzymatic assays performed 








































Figure 21: PCR-based dUTPase enzymatic activity assay. 
Plasmid pGPD2 was used a template to amplify the approximately 1 kb region 
between T7 and M13Rev primers. PCR products were run on 1% agarose gel and 
stained with SYBR-Green. A) PCR reactions using Taq DNA Polymerase and B) PCR 
reactions using MyTaq DNA Polymerase. For both A and B, the table below states 
what each lane contains. Lanes 4-13 all contain A, C, and G as well in addition to T 
or U as indicated. Reactions either contained DMSO, molecule #4, or molecule #5 as 
indicated on the right of the gel picture. The PCR reactions shown are only a single 
replicate from a set of three individual reactions. The average band intensity below 
lanes 12 and 13 is calculated in reference to Lane 9; *the quantification for Molecule 
#4 under B is an average of 2 replicates.  
1: A T C G 4: T incubated with H2O  9: U incubated with H2O 
2: A U C G 5: T incubated with yDut1 10: U incubated with yDut1 
3: A C G 6: T incubated with hDUT 11: U incubated with hDUT 
 7: T incubated with tbdUTPase #2 12: U incubated with tbdUTPase #2 
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 Using S. cerevisiae as a model system is an effective and efficient method to 
perform a pharmacological study [44]. Yeast is an easy to manage organism and 
experiments can be performed relatively quickly and provide the ability to replicate 
results more productively in comparison to other organisms. For the purpose of this 
project, yeast was to be used as a model system to express and study the essential 
enzyme dUTPase of the parasite T. brucei and also of humans. This is ideal because 
yeast is widely used as a model organism to test functions of human genes and 
enzymes [45]. In this case, a drug screen would have been performed to find a 
molecule that inhibits the function of the dUTPase from T. brucei, but would have no 
effect on human dUTPase, along with no effect on yeast itself. Having no harmful 
effect on yeast may indicate the found molecule(s) may not be toxic to human cells 
as well due to their similarities. Unfortunately, I was not able to use yeast as a model 
system to demonstrate functional. That is, the tests performed were not able to prove 
that, when human or T. brucei dUTPases were added to the yeast genome, they 
functionally complement the absence of endogenous Dut1 in the strain YNK425 in 
the presence of auxin.   
 Due to the fact that a physical drug screen could not be performed with yeast 
cells containing human and T. brucei dUTPase, we chose to perform a virtual drug 
screen. The Glide platform allowed for thousands of molecules available through 
their online database to be screened against tbdUTPase. The HTVS screen is the 
fastest screening tool in the software, which does leave room for error in terms of 
finding the right molecule and may have led to extra positive hits. However, because 
we also needed to determine if those molecules bound to hDUT, we allowed for a 
more stringent screen to be performed. The 13 molecules were found that fit our 
criteria of 1) binding to tbdUTPase, 2) not binding to human dUTPase, 3) drug-like 
chemical property, and 4) nucleotide-like structure.  The list included a well-known 
drug carbamazepine. These molecules were tested directly on T. brucei. If none of 
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these molecules showed any signs of killing the parasite, then a different approach 
would have been taken to find something that targets the essential dUTPase 
enzyme.  
 Out of the 13 molecules tested, molecule #4 was shown to significantly kill T. 
brucei with another molecule (#5) showing partial killing. 13 molecules is not a lot of 
candidates to screen through so for one to give the desired result was again very 
promising. Next, we tested whether molecule #4 was a dUTPase specific inhibitor, or 
whether its presence affected another pathway or essential enzyme leading to the 
parasite’s cell death. Being able to purify our proteins of interest, allowed us to 
directly test if molecule #4 is indeed inhibit dUTPase activity. Both the PiPer 
Pyrophosphate Assay Kit and PCR-based dUTPase enzymatic activity assay, which 
are standard methods to test the activity of dUTPases in the presence of molecule 
#4. Although the results of the PiPer assay were inconclusive due to the failure of 
controls, the results of PCR-based assay showed all of the positive and negative 
controls were working properly.  However, this assay showed that neither molecule 
#4 or #5 is an inhibitor of dUTPase.  
 There are a few different things that could be done to possibly achieve better 
results. Firstly, modifying the experiments that have already been done could provide 
us with our expected results. The AID system was used as a conditional knockdown 
method to be able to study the essential protein dUTPase. As stated, and shown in 
the results, the AID system was not very consistent when it came to growing cultures 
in the presence of auxin. Several times the survival rates and growth curves were 
not as expected due to the possible growth of suppressor mutations, which rendered 
the AID system ineffective. In our lab, the pTET system has been successfully used 
to create conditional knockouts. The endogenous yDUT1 could be under the control 
of a tetracycline inducible promoter (pTET). Human and T. brucei dUTPase genes 
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could be transformed into the cells and the expression of the endogenous yDUT1 
could be turned off, allowing for complementation to occur.  
 Another experiment that may be changed would be protein purification. 
Protein purification can be a rigorous process and does indeed take a significant 
amount of time to get the proper overexpression and washing conditions to get a 
valuable, pure purified protein. Revisiting the purification protocols and trying 
different overexpression inducers, protein tag, and washing buffers could most 
definitely result in a purer sample to be purified.  
 When the dUTPase genes were integrated into the yeast genome at the HO 
locus, the AID system no longer seemed to be properly functioning. Instead of 
adding the dUTPase genes at a different locus, the genes can be directly added to 
replace the endogenous DUT1 gene. One of ways to accomplish this is to instead 
use a diploid yeast strain. in a diploid strain, there are two copies of DUT1. Either 
human or T. brucei dUTPase genes can be swapped out with one of the copies of 
the endogenous DUT1 via homologous recombination and the yeast cell will still be 
viable because it still contains the other DUT1 copy. Plasmids with the expression 
cassette for either hDUT or tbdUTPase can be transformed into the diploid cells. The 
diploid cells containing one copy of yDUT1 gene and a plasmid-born hDUT or 
tbdUTPase gene can be induced to undergo sporulation, which results in a tetrad of 
four haploid spores [46]. These spores can then be separated via micromanipulation, 
and then grown in rich medium.  If hDUT or tbdUTPase can functionally complement 
the loss of yDut1, some of the spores will contain the deletion at endogenous DUT1 
locus along with the plasmid.  If functional complementation is not possible, no 
spores with the deletion at endogenous DUT1 locus will be able to survive.  
 Another method to test for functional complementation is called plasmid 
shuffling. The purpose of plasmid shuffling is to introduce two plasmids to your Ura- 
and Leu- cell strain, one plasmid containing WT yDUT1 with a URA3 marker and the 
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second plasmid containing hDUT with a LEU2 marker [47]. First, the strain is grown 
in rich media and transformed with the WT yDUT1 URA3 plasmid and cells are 
selected for and grown in Ura-.  The endogenous DUT1 gene can at this point 
deleted without loss of cell viability due to the plasmid expressed DUT1. The second 
hDUT-LEU2 plasmid is then also transformed and then selected for in Ura- and Leu-. 
Colonies that grow should contain both plasmids. The colonies can be replica plated 
onto 5-FOA plates to select for cells that lost the WT yDUT1-URA3 plasmid.  If hDUT 
can functionally complement the loss of yeast Dut1, colonies containing only the 
hDUT-LEU2 plasmid should be viable. The viable cells can then be further tested for 
complementation. The same experiments can be done with tbdUTPase-LEU2 
plasmid to test whether T. brucei dUTPase enzyme can functionally complement the 
yeast protein. 
 Lastly, we have directly showed that molecule #4 kills T. brucei. The best way 
to see how it is killing the cells is by directly studying it in T. brucei. Molecule #4 
consists of a single S atom in its structure. A chemically synthetic form of this 
molecule could be generated using the radioactive isotope 35S and then used to treat 
the parasite [48]. This synthetic molecule should can be tracked where in the 
parasite it localizes to in order to see how the molecule might be affecting the 
viability of T. brucei. The 35S can be tracked with various microscopy and 
autoradiography methods. 
 I was unable to show that the addition of human or T. brucei dUTPase can 
complement in the absence of the endogenous yeast dUTPase and failed to identify 
a tbdUTPase-specific ligand. However, through this project a single small molecule 
was found to kill T. brucei directly and have no effect on yeast. Since the dUTPase 
pathway is well studied, I believe it still holds promise in terms of having potential as 
viable drug target to combat T. brucei infections. Furthermore, with the world 
adapting to computers and technology being involved more and more in all fields, 
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virtual drug screening has the potential to change the pharmaceutical industry. The 
results presented here show a promising method and provides an opportunity to 
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